Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Fosmanogepix by Basilea Pharmaceutica for Candidiasis: Likelihood of Approval
Fosmanogepix is under clinical development by Basilea Pharmaceutica and currently in Phase II for Candidiasis. According to GlobalData, Phase II...
Ceftobiprole medocaril by Basilea Pharmaceutica for Skin And Skin Structure Infections (SSSI): Likelihood of Approval
Ceftobiprole medocaril is under clinical development by Basilea Pharmaceutica and currently in Phase III for Skin And Skin Structure Infections...
Ceftobiprole medocaril by Basilea Pharmaceutica for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections: Likelihood of Approval
Ceftobiprole medocaril is under clinical development by Basilea Pharmaceutica and currently in Phase III for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections....
Ceftobiprole medocaril by Basilea Pharmaceutica for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections: Likelihood of Approval
Ceftobiprole medocaril is under clinical development by Basilea Pharmaceutica and currently in Phase III for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections....
Ceftobiprole medocaril by Basilea Pharmaceutica for Sepsis: Likelihood of Approval
Ceftobiprole medocaril is under clinical development by Basilea Pharmaceutica and currently in Phase III for Sepsis. According to GlobalData, Phase...
Derazantinib hydrochloride by Basilea Pharmaceutica for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
Derazantinib hydrochloride is under clinical development by Basilea Pharmaceutica and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell...